Ποια είναι η τιμή για InnoPharmax Inc. (4172)

Η τιμή για InnoPharmax Inc. (4172) είναι $0.35614911

Ποια είναι η κεφαλαιοποίηση αγοράς για InnoPharmax Inc. (4172)

Η κεφαλαιοποίηση αγοράς για InnoPharmax Inc. (4172) είναι $41.95M

InnoPharmax Inc. (4172) Τιμή και Κεφαλαιοποίηση Αγοράς

InnoPharmax Inc., established in 1994 and headquartered in Taipei, Taiwan, operates as a specialized pharmaceutical enterprise. The company's core activities revolve around the development and market introduction of therapeutic products, with a particular focus on oncology and various other specialized medical fields within the Taiwanese market. Their current commercial portfolio encompasses N11005, an oral insulin designed for administration with meals, alongside GemOral. They also provide an Imipenem and Cilastatin solution, utilized for treating a broad spectrum of bacterial infections affecting areas such as the lower respiratory tract, skin and soft tissue, internal abdominal organs, gynecological systems, and bone and joints. Furthermore, InnoPharmax offers contrast agents, specifically gadopentetate dimeglumine and gadodiamide; oncology medications like Innomustine and Immurin; and Inpheno tablets, which are indicated for rare diseases. The company also provides advanced technology platforms, including the MUCR system, OralPas, and OralPas Pro. Looking at its research and development pipeline, InnoPharmax has several promising candidates. D07001 is currently in Phase I clinical trials for tumor treatment. C08001 has progressed to Phase III, targeting hypertension, heart failure, and left ventricular dysfunction following a myocardial infarction. Additional compounds in pilot bioequivalence (BE) trials include D07002, a potential supplement for phenylketonuria; C07001 for the management of Parkinson's disease; and N11001, which is being investigated for urological applications. The company is also actively formulating new contrast agents, D0131502 and D0051301.

Η τιμή για 4172	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$44,428.65 $41.95M	NVDA	$5.233T	+12,474,631.49%
$39,469.74 $41.95M	AAPL	$4.649T	+11,082,262.60%
$34,820.33 $41.95M	GOOG	$4.101T	+9,776,795.95%
$30,343.96 $41.95M	MSFT	$3.574T	+8,519,915.37%
$23,831.90 $41.95M	AMZN	$2.807T	+6,691,450.52%

Η τιμή για 4172

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$44,428.65 $41.95M